2023 Q3 Form 10-Q Financial Statement

#000165495423012662 Filed on October 06, 2023

View on sec.gov

Income Statement

Concept 2023 Q3
Revenue $0.00
YoY Change
Cost Of Revenue $0.00
YoY Change
Gross Profit $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $19.83K
YoY Change -32.02%
% of Gross Profit
Research & Development $0.00
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $19.83K
YoY Change -32.02%
Operating Profit -$19.83K
YoY Change -32.02%
Interest Expense $2.824K
YoY Change 180.72%
% of Operating Profit
Other Income/Expense, Net -$2.824K
YoY Change -17.18%
Pretax Income -$22.65K
YoY Change -30.48%
Income Tax
% Of Pretax Income
Net Earnings -$22.65K
YoY Change -30.47%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.00
COMMON SHARES
Basic Shares Outstanding 21.30M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $27.41K
YoY Change 109.56%
Cash & Equivalents $27.41K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $120.7K
YoY Change -11.47%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $120.7K
Total Long-Term Assets $0.00
Total Assets $120.7K
YoY Change -11.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $91.93K
YoY Change 20.5%
Accrued Expenses $8.448K
YoY Change -28.16%
Deferred Revenue
YoY Change
Short-Term Debt $111.1K
YoY Change 117.12%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $211.5K
YoY Change 51.9%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $211.5K
Total Long-Term Liabilities $0.00
Total Liabilities $211.5K
YoY Change 51.9%
SHAREHOLDERS EQUITY
Retained Earnings -$3.520M
YoY Change 3.99%
Common Stock $21.30K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$90.82K
YoY Change
Total Liabilities & Shareholders Equity $120.7K
YoY Change -11.47%

Cashflow Statement

Concept 2023 Q3
OPERATING ACTIVITIES
Net Income -$22.65K
YoY Change -30.47%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$110.00
YoY Change -102.4%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $5.450K
YoY Change -33.29%
Cash From Investing Activities $5.450K
YoY Change -33.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -110.0
Cash From Investing Activities 5.450K
Cash From Financing Activities 0.000
Net Change In Cash 5.340K
YoY Change -143.59%
FREE CASH FLOW
Cash From Operating Activities -$110.00
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
11440 usd
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21303000 shares
us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2023Q3 us-gaap Accounts And Notes Receivable Net
AccountsAndNotesReceivableNet
93249 usd
CY2023Q1 us-gaap Accounts And Notes Receivable Net
AccountsAndNotesReceivableNet
106868 usd
hbr Seniorsecuredcreditline
SENIORSECUREDCREDITLINE
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 4. SENIOR SECURED CREDIT LINE</strong> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Senior Secured Convertible Credit Line</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On July 1, 2022, the Company entered a secured convertible note up to $100,000. The secured convertible note matures on July 1, 2023 and bears interest at 8% per annum. The convertible note is secured by 11,000,000 shares of the Company’s common stock held by the Company’s CEO. In the event of an event of default on the note, at the option of the holder, the note can be converted into shares of the Company’s common stock at the conversion price of $0.01 per share. On July 12, 2023, the Company amended the secured convertible note of $100,000 issued on July 1, 2022. The amended secured convertible note was increased to $150,000 and is due on January 1, 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of August 31, 2023 and February 28, 2023, the Company has drawn $104,103 and $78,271 on the convertible note, respectively.</p>
CY2022Q3 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
100000 usd
CY2022Q3 us-gaap Debt Instrument Description
DebtInstrumentDescription
The convertible note is secured by 11,000,000 shares of the Company’s common stock held by the Company’s CEO. In the event of an event of default on the note, at the option of the holder, the note can be converted into shares of the Company’s common stock at the conversion price of $0.01 per share
CY2023Q3 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
104103 usd
CY2023Q1 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
78271 usd
us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
21819 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1580000 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.57
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1580000 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.57
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
1260466 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y9M14D
CY2023Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
dei Entity Central Index Key
EntityCentralIndexKey
0001796949
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--02-28
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21303000 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21303000 shares
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21303000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
0
CY2023Q1 us-gaap Advances To Affiliate
AdvancesToAffiliate
7000 usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-08-31
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-56214
dei Entity Registrant Name
EntityRegistrantName
Healthcare Business Resources Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-3639946
dei Entity Address Address Line1
EntityAddressAddressLine1
718 Thompson Lane
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 108-273
dei Entity Address City Or Town
EntityAddressCityOrTown
Nashville
dei Entity Address State Or Province
EntityAddressStateOrProvince
TN
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
37204
dei City Area Code
CityAreaCode
615
dei Local Phone Number
LocalPhoneNumber
856-5542
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
21303000 shares
CY2023Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
27411 usd
CY2023Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
14192 usd
CY2023Q3 us-gaap Accounts And Notes Receivable Net
AccountsAndNotesReceivableNet
93249 usd
CY2023Q1 us-gaap Accounts And Notes Receivable Net
AccountsAndNotesReceivableNet
106868 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
120660 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
121060 usd
CY2023Q3 us-gaap Assets
Assets
120660 usd
CY2023Q1 us-gaap Assets
Assets
121060 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
91931 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
91143 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8448 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3368 usd
CY2023Q3 us-gaap Advance Rent
AdvanceRent
7000 usd
CY2023Q1 us-gaap Advance Rent
AdvanceRent
7000 usd
CY2023Q3 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
104103 usd
CY2023Q1 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
78271 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
211482 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
179782 usd
CY2023Q3 us-gaap Liabilities
Liabilities
211482 usd
CY2023Q1 us-gaap Liabilities
Liabilities
179782 usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
21303 usd
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
21303 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3408074 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3386255 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3520199 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3466280 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-90822 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-58722 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
120660 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
121060 usd
CY2023Q3 hbr Revenue
Revenue
0 usd
CY2022Q3 hbr Revenue
Revenue
0 usd
hbr Revenue
Revenue
0 usd
hbr Revenue
Revenue
1884 usd
CY2023Q3 us-gaap Revenues
Revenues
0 usd
CY2022Q3 us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
1884 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10452 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8522 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23143 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26580 usd
CY2023Q3 us-gaap Professional Fees
ProfessionalFees
9376 usd
CY2022Q3 us-gaap Professional Fees
ProfessionalFees
20646 usd
us-gaap Professional Fees
ProfessionalFees
25525 usd
us-gaap Professional Fees
ProfessionalFees
68000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
19828 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
29168 usd
us-gaap Operating Expenses
OperatingExpenses
48668 usd
us-gaap Operating Expenses
OperatingExpenses
94580 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-19828 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-29168 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-48668 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-92696 usd
CY2023Q3 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 usd
CY2022Q3 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
-2404 usd
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 usd
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
14906 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
2824 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
1006 usd
us-gaap Interest Expense
InterestExpense
5251 usd
us-gaap Interest Expense
InterestExpense
7746 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2824 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3410 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5251 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7160 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-22652 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-32578 usd
us-gaap Net Income Loss
NetIncomeLoss
-53919 usd
us-gaap Net Income Loss
NetIncomeLoss
-85536 usd
CY2023Q3 hbr Loss Per Share Basic
LossPerShareBasic
-0.00
CY2022Q3 hbr Loss Per Share Basic
LossPerShareBasic
-0.00
hbr Loss Per Share Basic
LossPerShareBasic
-0.00
hbr Loss Per Share Basic
LossPerShareBasic
-0.00
CY2023Q3 hbr Loss Per Share Diluted
LossPerShareDiluted
-0.00
CY2022Q3 hbr Loss Per Share Diluted
LossPerShareDiluted
-0.00
hbr Loss Per Share Diluted
LossPerShareDiluted
-0.00
hbr Loss Per Share Diluted
LossPerShareDiluted
-0.00
CY2023Q3 hbr Weighted Average Shares Outstanding Basic
WeightedAverageSharesOutstandingBasic
20853000 shares
CY2022Q3 hbr Weighted Average Shares Outstanding Basic
WeightedAverageSharesOutstandingBasic
20853000 shares
hbr Weighted Average Shares Outstanding Basic
WeightedAverageSharesOutstandingBasic
20853000 shares
hbr Weighted Average Shares Outstanding Basic
WeightedAverageSharesOutstandingBasic
20853000 shares
CY2023Q3 hbr Weighted Average Shares Outstanding Diluted
WeightedAverageSharesOutstandingDiluted
20853000 shares
CY2022Q3 hbr Weighted Average Shares Outstanding Diluted
WeightedAverageSharesOutstandingDiluted
20853000 shares
hbr Weighted Average Shares Outstanding Diluted
WeightedAverageSharesOutstandingDiluted
20853000 shares
hbr Weighted Average Shares Outstanding Diluted
WeightedAverageSharesOutstandingDiluted
20853000 shares
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-58722 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-31267 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-78549 usd
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
10379 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-22652 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-90822 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-171369 usd
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
16326 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-52958 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-208001 usd
CY2022Q3 hbr Common Shares Issued For Settlement Of Note Payable Related Party Amount
CommonSharesIssuedForSettlementOfNotePayableRelatedPartyAmount
225000 usd
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
12639 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-32578 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-2940 usd
us-gaap Profit Loss
ProfitLoss
-53919 usd
us-gaap Profit Loss
ProfitLoss
-85536 usd
us-gaap Share Based Compensation
ShareBasedCompensation
21819 usd
us-gaap Share Based Compensation
ShareBasedCompensation
28965 usd
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
0 usd
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-14906 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
26620 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
50711 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
5080 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-8513 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-400 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29279 usd
us-gaap Proceeds From Sale Of Notes Receivable
ProceedsFromSaleOfNotesReceivable
13619 usd
us-gaap Proceeds From Sale Of Notes Receivable
ProceedsFromSaleOfNotesReceivable
16343 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
13619 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
16343 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
175000 usd
hbr Proceeds From Notes Payable Related Party
ProceedsFromNotesPayableRelatedParty
0 usd
hbr Proceeds From Notes Payable Related Party
ProceedsFromNotesPayableRelatedParty
225000 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
0 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
50000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
13219 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-12936 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14192 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26013 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27411 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13077 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
5135 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Securities Borrowed Credit Loss Expense Reversal
SecuritiesBorrowedCreditLossExpenseReversal
25832 usd
us-gaap Securities Borrowed Credit Loss Expense Reversal
SecuritiesBorrowedCreditLossExpenseReversal
51174 usd
hbr Common Shares Issued For Settlement Of Note Payable Related Party
CommonSharesIssuedForSettlementOfNotePayableRelatedParty
0 usd
hbr Common Shares Issued For Settlement Of Note Payable Related Party
CommonSharesIssuedForSettlementOfNotePayableRelatedParty
225000 usd
CY2023Q2 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
100000 usd
hbr Increased Decreased In Convetible Note Amount
IncreasedDecreasedInConvetibleNoteAmount
150000 usd
CY2023Q3 us-gaap Advances To Affiliate
AdvancesToAffiliate
7000 usd

Files In Submission

Name View Source Status
0001654954-23-012662-index-headers.html Edgar Link pending
0001654954-23-012662-index.html Edgar Link pending
0001654954-23-012662.txt Edgar Link pending
0001654954-23-012662-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hbr-20230831.xsd Edgar Link pending
hbr_10q.htm Edgar Link pending
hbr_ex311.htm Edgar Link pending
hbr_ex312.htm Edgar Link pending
hbr_ex321.htm Edgar Link pending
hbr_ex322.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
hbr-20230831_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
hbr-20230831_pre.xml Edgar Link unprocessable
hbr-20230831_lab.xml Edgar Link unprocessable
hbr_10q_htm.xml Edgar Link completed
hbr-20230831_def.xml Edgar Link unprocessable